Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Bowling EA, Wang JH, Gong F, Wu W, et al. Cell 2021 Jan 13. pii: S0092-8674(20)31753-0. doi: 10.1016/j.cell.2020.

Read + Share

Amedeo Smart

Independent Medical Education

Bowling EA, Wang JH, Gong F, Wu W, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell 2021 Jan 13. pii: S0092-8674(20)31753-0. doi: 10.1016/j.cell.2020.
PMID: 33450205